retatrutide dosing study latest trial results clinical trials phase approval: FDA status, results, and when it could be available Do not obsess over Retatrutide. – Phase III retatrutide demonstrates – retatrutide dosing clinical trials trial

Full generic competition is expected in late 2026 when Mercks key patent expires which should further reduce prices

and many other regions and are supplied strictly for laboratory research purposes

Tosti, A., Guidetti, M

Limited Long-Term Data Mounjaro only approved in 2022 Zepbound only approved in 2023 Long-term safety profile still emerging Unknown effects of decades-long use 2

Its subject to a progressive decline in elasticity, smoothness, and even skin tone as a consequence of cumulative damage as we age

Pro-atherosclerotic risk factors in the blood can damage the endothelium, which acts as the initiation of AS and causes its progression